TICKERNERD
Menu
ENOVENOVHealthcare · Medical Devices

ENOV Stock Forecast: Enovis Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$26
−0.46% on the day

The 13 Wall Street analysts covering Enovis Corp. hold a median 12-month price target of $40 — +53.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.5B
Ticker Nerd rank
86 / 100
Median analyst target
$40
Analysts covering
13
Total return, dividends reinvested
1W
0.0%
1M
−3.8%
YTD
−2.2%
1Y
−11.7%
From 52W high
−21.8%
From 52W low
+30.0%
$20
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENOV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Enovis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Value
97
Issuance
78
Growth
76
Quality
63
Revisions
52
Volatility
44
Momentum
42
Size
40

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (42): The shares have been drifting down relative to others.

Size (40): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENOV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENOV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26ENOVHigh $55Median $40Low $28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says13 analysts
12 Buy1 Hold0 Sell
Low $28Median $40High $55

The green dot is the last close — the median target sits +53.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
17 Aug 2026Canaccord GenuityMaintainsBuy$50 → $45
7 Aug 2026Wells FargoMaintainsOverweight—
7 Aug 2026Wells FargoMaintainsOverweight$40 → $39
6 Aug 2026BTIGMaintainsBuy—
6 Aug 2026BTIGMaintainsBuy$39 → $40
28 July 2026UBSAssumesBuy$50 → $51
9 July 2026BMO CapitalInitiatesOutperform$29
9 July 2026BMO CapitalInitiatesOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$36 → $32
6 July 2026Evercore ISI GroupMaintainsOutperform—
22 May 2026BTIGReiteratesBuy—
8 May 2026Evercore ISI GroupMaintainsOutperform—
8 May 2026Wells FargoMaintainsOverweight—
17 Apr 2026William BlairAssumesOutperform—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
26 Feb 2026BTIGMaintainsBuy—
26 Feb 2026NeedhamMaintainsBuy—
6 Jan 2026BTIGInitiatesBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
17 Dec 2025Freedom Capital MarketsInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENOV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ENOV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.4%
Analysts raising
2
Analysts cutting
3
Fundamentals

Enovis Corp. (ENOV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.3×

Cheaper than 83% of US stocks

Price / sales
0.7×

Cheaper than 78% of US stocks

Price / book
1.0×

Cheaper than 73% of US stocks

EV / EBITDA
7.5×

Cheaper than 47% of US stocks

Growth & margins
Revenue growth (YoY)
3.2%

Higher than 35% of US stocks

Earnings growth (YoY)
3.2%

Higher than 40% of US stocks

Gross margin
61.6%

Higher than 75% of US stocks

Operating margin
4.2%

Higher than 53% of US stocks

Net margin
−48.0%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−54.1%

Higher than 20% of US stocks

Return on assets
1.2%

Higher than 51% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ENOV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ENOVEnovis Corp.$1.5B
86
TNDMTandem Diabetes Care, Inc.$1.6B
64
ATECAlphatec Holdings, Inc.$1.4B
76
CNMDCONMED Corp.$1.6B
96
AORTArtivion, Inc.$1.4B
45
IARTIntegra LifeSciences Holdings Corp.$1.3B
89
INSPInspire Medical Systems, Inc.$1.8B
81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Enovis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENOV news & analysis

Enovis Corporation: Arvis Is Disrupting The Health Care Industry

Seeking Alpha · 21 Aug 2026positive

An article discusses Enovis Corporation's Arvis, a wearable augmented reality device for orthopedic surgery that has achieved full commercialization and targets the ambulatory surgery center market. The piece notes Enovis's weak fundamentals—slim margins, high leverage, and thin free cash flow—but argues these are already priced in while Arvis's growth potential is not.

Why it matters — ENOV watchers would care because the article highlights Arvis's commercialization as a potential growth catalyst for the company despite its currently weak financial fundamentals.

Enovis: Executing Better, But Still Remains Stuck In A Med-Tech No Man's Land

Seeking Alpha · 20 Aug 2026neutral

Enovis reported Q2 results that beat expectations, with 4% organic revenue growth, improved margins, and market-share gains in joint reconstruction driven by new products and competitor disruptions. The company is making progress on cash-flow conversion and deleveraging, aiming for sub-2.0x net debt/EBITDA within three years, though guidance now points to a more Q4-weighted second half.

Why it matters — ENOV watchers would care because the results confirm improving operational execution and financial deleveraging, even as the company continues to face strategic positioning challenges in the med-tech landscape.

Enovis Q2 Earnings Call Highlights

MarketBeat · 8 Aug 2026positive

Enovis reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, with growth in its Reconstruction business offsetting a slower but still expanding Performance & Recovery segment. Management attributed results to improved commercial execution, new-product adoption and operational productivity, while noting pressure from Middle East-related disruptions and higher inflation.

Why it matters — A ENOV watcher would care because the quarter shows continued revenue growth driven by commercial execution and new-product adoption, alongside headwinds from Middle East disruptions and inflation that could affect the outlook.

Enovis Corporation (ENOV) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Enovis Corporation held its Q2 2026 earnings call, and a transcript of the call has been published on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management discussion.

Why it matters — A transcript of the quarterly earnings call gives Enovis investors direct access to management's commentary on the company's latest financial performance and outlook.

Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Enovis (ENOV) reported Q2 earnings of $0.90 per share, surpassing the Zacks Consensus Estimate of $0.83 per share and up from $0.79 per share a year ago. The company also beat revenue estimates for the quarter.

Why it matters — ENOV watchers would note that the company surpassed both earnings and revenue expectations, indicating a stronger-than-expected quarterly performance.

FAQ

Frequently asked questions about ENOV stock

What is the ENOV stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Enovis Corp. have a median 12-month price target of $40, with estimates ranging from $28 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENOV stock a buy right now?

Of the 13 analysts covering Enovis Corp., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enovis Corp. 86 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENOV?

As at 22 Aug 2026, Enovis Corp. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

Will ENOV stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +53.5% from the last close, and Ticker Nerd's factor model ranks Enovis Corp. 86 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENOV stock forecast for 2030?

No analyst covering Enovis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENOV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $55 over the next 12 months.

How has ENOV stock performed over the past year?

Enovis Corp. returned -11.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enovis Corp. do?

Enovis Corporation is a diversified healthcare equipment company focused on developing and supplying a broad range of innovative medical technology solutions. The primary function of the company is to enhance patient care and improve treatment outcomes across various medical specialties.

What is the latest news on ENOV?

The most recent item we track (Seeking Alpha, 21 Aug 2026): "Enovis Corporation: Arvis Is Disrupting The Health Care Industry". An article discusses Enovis Corporation's Arvis, a wearable augmented reality device for orthopedic surgery that has achieved full commercialization and targets the ambulatory surgery center market. The piece notes Enovis's weak fundamentals—slim margins, high leverage, and thin free cash flow—but argues these are already priced in while Arvis's growth potential is not.

Company

About Enovis Corp.

Enovis Corporation is a diversified healthcare equipment company focused on developing and supplying a broad range of innovative medical technology solutions. The primary function of the company is to enhance patient care and improve treatment outcomes across various medical specialties. Enovis is known for its advanced surgical solutions, rehabilitation devices, and other healthcare innovations that serve both healthcare providers and patients. The company's products cater to sectors such as orthopedics, pain management, and wound care, offering a significant impact on surgical efficiencies and patient recovery. By providing a comprehensive portfolio of medical solutions, Enovis plays a vital role in the healthcare industry, supporting the demands of hospitals, clinics, and healthcare professionals. In the financial market, Enovis Corporation holds significance as it merges cutting-edge technology with healthcare services, contributing to the advancement of medical science and the betterment of patient-centric care. Its commitment to research and development underscores its role in shaping the future of healthcare, offering both therapeutic benefits and operational efficiencies.

CEO Mr. Damien McDonald · 7,367 employees · United States · https://www.enovis.com